Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.

Article  CAS  PubMed  Google Scholar 

Armandi A, Bugianesi E. Natural history of NASH. Liver Int. 2021;41(Suppl 1):78–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56:942–56.

Article  CAS  PubMed  Google Scholar 

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

Article  CAS  PubMed  Google Scholar 

Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.

Article  PubMed  Google Scholar 

Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–61.

Article  PubMed  Google Scholar 

Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77:607–18.

Article  CAS  PubMed  Google Scholar 

Stiede K, Miao W, Blanchette HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology. 2017;66:324–34.

Article  CAS  PubMed  Google Scholar 

Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463-73.e6.

Article  CAS  PubMed  Google Scholar 

Westlin W, Harriman G, Harwood H, et al. NDI-010976, a potent, liver-directed, oral inhibitor of acetyl Coa carboxylase for non-alcoholic steatohepatitis: a phase 1 single ascending dose study in healthy volunteers. J Hepatol. 2016;64:S501–2.

Article  Google Scholar 

Weber E, Younis IR, Nelson C, et al. Effect of renal impairment on the pharmacokinetics of firsocostat, an acetyl-coenzyme A carboxylase inhibitor, and cilofexor, a selective nonsteroidal farnesoid X receptor agonist. J Clin Pharmacol. 2023;63:560–8.

Article  CAS  PubMed  Google Scholar 

Hsueh C-H, Qin A, West S, Chung C, Othman A. A phase 1 mass balance study of firsocostat, a liver-targeted acetyl-CoA carboxylase inhibitor. Clin Pharmacol Ther. 2022;111:S24.

Google Scholar 

Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105:1345–61.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Li P, Zhang Z, et al. Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes. Int J Mol Sci. 2020;21:7023.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uchaipichat V, Mackenzie PI, Guo X-H, et al. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004;32:413–23.

Article  CAS  PubMed  Google Scholar 

Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka FK. The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles. Pharmaceutics. 2021;13:1961.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krupka E, Venisse N, Lafay C, et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol. 2006;62:653–9.

Article  CAS  PubMed  Google Scholar 

Ayala RC, Arya V, Younis IR. Design features of drug–drug interaction trials between antivirals and oral contraceptives. J Clin Pharmacol. 2016;56:541–7.

Article  CAS  PubMed  Google Scholar 

Bioanalytical method validation. Guidance for Industry. United States Food and Drug Administration; 2018. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry. Accessed 28 Aug 2023.

Patel PJ, Hayward KL, Rudra R, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: implications for disease severity and management. Medicine (Baltimore). 2017;96: e6761.

Article  PubMed  Google Scholar 

Weiss HM, Langenickel T, Cain M, et al. Clinical investigation of metabolic and renal clearance pathways contributing to the elimination of fevipiprant using probenecid as perpetrator. Drug Metab Dispos. 2021;49:389–94.

Article  CAS  PubMed  Google Scholar 

Devineni D, Vaccaro N, Murphy J, et al. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015;53:115–28.

Article  CAS  PubMed  Google Scholar 

Kirby BJ, Lutz JD, Yue MS, et al. Organic anion transporting polypeptide inhibition dramatically increases plasma exposure but not pharmacodynamic effect nor inferred hepatic intracellular exposure of firsocostat. Clin Pharmacol Ther. 2021;109:1334–41.

Article  CAS  PubMed  Google Scholar 

Drugs. United States Food and Drug Administration. Available at: https://www.fda.gov/drugs. Accessed 20 Sep 2023.